Relatório sobre “Retrato da Investigação e Inovação em Cancro em Portugal” apresentado em setembro
Cumprindo o seu objetivo de promover a investigação em cancro em Portugal, nomeadamente através da recolha de indicadores e disseminação de resultados, bem como da análise e proposta de soluções para os constrangimentos existentes na investigação nacional em Oncologia, a ASPIC, com o apoio da Fundação “la Caixa”, Fundação Calouste Gulbenkian e Novartis, promoveu a recolha e análise de dados sobre investigação e inovação em cancro em Portugal nos últimos 10 anos.
A apresentação pública deste relatório, denominado «Retrato da Investigação e Inovação em Cancro em Portugal», realiza-se a 13 de setembro de 2022, entre as 9h00 e as 14h00, no auditório 3 da Fundação Calouste Gulbenkian, em Lisboa.
A inscrição é gratuita, mas de registo obrigatório por questões relacionadas com a capacidade da sala. Pode registar-se aqui.
PROGRAMA PRELIMINAR
Related news
Researchers from IPO Porto develop algorithm to improve cervical cancer screening
Researchers from the Epigenetics & Cancer Biology Group at the IPO Porto Research Center, in collaboration with the Pathology and Clinical Pathology Services, have developed an algorithm to improve the screening of women who test positive for HPV infection in the Population Cervical Cancer Screening Program implemented in the Northern region of the country. Based…
Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets
Medulloblastoma is a common and aggressive type of brain tumor in children, consisting of four molecular subgroups. Traditional methods of treatment with surgery, radiotherapy and chemotherapy result in an incomplete response with serious side effects. Immunotherapy using the blockade of immune checkpoints such as PD-1, PD-L1 and CTLA4 has increased its prominence in solid tumor…
LiKidMiRs: A ddPCR-Based Panel of 4 Circulating miRNAs for Detection of Renal Cell Carcinoma
Cancer mortality reduction remains a major societal goal, in part materialized in the many efforts to develop effective biomarkers for early detection. Early detection of renal cell carcinoma (RCC) significantly increases the likelihood of curative treatment, avoiding the need for subsequent therapies, which have side effect and entail more comorbidities. Thus, the research team from…
The risk of colorectal cancer in patients with Inflammatory Bowel Disease
Patients with inflammatory bowel disease (IBD), which includes Crohn’s Disease and Ulcerative Colitis, are at increased risk of developing colorectal cancer (CRC) when compared to the general population. Colorectal cancer associated with long-lasting (more than 8-10 years of diagnosis) bowel inflammation (colitis) is one of the major complications of inflammatory bowel disease. The mechanisms underlying…
Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis
Skin cancer (SC) is one of the most common types of cancer in the world population, with an increasing annual incidence rate. The p53 protein plays a crucial role in skin tumorigenesis, and its function is often compromised due to mutations induced by ultraviolet radiation (UVB). Currently, sunscreen is the most recommended agent for the…
Study reveals the role of epigenetics in prostate cancer radioresistance
Researchers from the Cancer Biology & Epigenetics Group at the Research Center of IPO Porto, Portugal have revealed a pivotal link between epigenetic regulation and prostate cancer radioresistance. The study, entitled “Epigenetic Regulation of TP53 is Involved in Prostate Cancer Radioresistance and DNA Damage Response Signaling,” was recently published in the prestigious journal Signal Transduction…
